MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

Venous leg ulcers affect about 2% of individuals aged 65 and older, with over 1.5 million new cases reported annually in the U.S., the company said. They typically develop on the lower extremities ...

12, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the initiation of VALUE, a global, pivotal ...

Skin Integrity Team has been shortlisted in three categories at this year’s Journal of Wound Care Awards, which take place ...

OhioHealth Mansfield Hospital is proud to announce its 100th placenta donation through Lifeline of Ohio’s Placenta Donation ...

In one particular study involving three patients with leg ulcers, Dooms-Goossens and Degreef discovered that the patients reacted to petrolatums on their leg ulcers despite having negative patch ...